- Nano Express
- Open Access
Enhanced anticancer activity of DM1-loaded star-shaped folate-core PLA-TPGS nanoparticles
- Xiaolong Tang†1, 2,
- Yong Liang†3,
- Yongqiang Zhu4,
- Shiyu Cai1,
- Leilei Sun5 and
- Tianyi Chen1Email author
© Tang et al.; licensee Springer. 2014
- Received: 22 June 2014
- Accepted: 2 October 2014
- Published: 9 October 2014
The efficient delivery of therapeutic drugs into interested cells is a critical challenge to broad application of nonviral vector systems. In this research, emtansine (DM1)-loaded star-shaped folate-core polylactide-d-α-tocopheryl polyethylene glycol 1000 succinate (FA-PLA-TPGS-DM1) copolymer which demonstrated superior anticancer activity in vitro/vivo in comparison with linear FA-PLA-TPGS nanoparticles was applied to be a vector of DM1 for FR+ breast cancer therapy. The DM1- or coumarin 6-loaded nanoparticles were fabricated, and then characterized in terms of size, morphology, drug encapsulation efficiency, and in vitro drug release. And the viability of MCF-7/HER2 cells treated with FA-DM1-nanoparticles (NPs) was assessed. Severe combined immunodeficient mice carrying MCF-7/HER2 tumor xenografts were treated in several groups including phosphate-buffered saline control, DM1, DM1-NPs, and FA-DM1-NPs. The antitumor activity was then assessed by survival time and solid tumor volume. All the specimens were prepared for formalin-fixed and paraffin-embedded tissue sections for hematoxylin-eosin staining. The data showed that the FA-DM1-NPs could efficiently deliver DM1 into MCF-7/HER2 cells. The cytotoxicity of DM1 to MCF-7/HER2 cells was significantly increased by FA-DM1-NPs when compared with the control groups. In conclusion, the FA-DM1-NPs offered a considerable potential formulation for FR+ tumor-targeting biotherapy.
- Emtansine (DM1)
- Targeting nanoparticles
- Drug delivery
Biodegradable nanoparticles served as drug carriers that could provide an ideal solution to most of the problems presented by anticancer drugs [1, 2]. When compared with standard administration, drug incorporation into nanoparticles shows a variety of advantages such as high stability, protection of incorporated labile drugs from degradation, controlled and sustained drug release, increased drug therapeutic efficacy, and reduced side effects [3, 4]. Polymers, including star-shaped cholic acid-core polylactide-d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) copolymer, PLA-TPGS-b-poly(ϵ-caprolactone-ran-lactide) (TPGS-b-(PCL-ran-PLA)) copolymer, and other structure copolymers, have been used to develop drug-loaded nanoparticles [5, 6].
Similar to vinca alkaloids, maytansine and its analogs emtansine (DM1) which are microtubule-targeted drugs binding to tubulin at the vinca binding site can depolymerize microtubules and arrest cells in mitosis, resulting in a powerful anti-mitotic activity [7–10]. Maytansine displays almost 100 times higher cytotoxicity in cells than the vinca alkaloids [11, 12]. Maytansine is effective against breast cancer, lung carcinoma, and murine melanocarcinoma solid tumors and has an antileukemic activity against lymphocytic leukemia in vivo. The microtubule-targeted antiproliferative activity of maytansine/maytansinoids was substantiated in a screening of 60 human cancer cell types by the U.S. National Cancer Institute . Although maytansine and DM1 efficiently inhibits microtubule assembly and then kills cancer cells, they demonstrated a small therapeutic window in human clinical trials [13, 14]. The limitation of maytansine and DM1 is their systemic toxicity such as neurotoxicity and gastrointestinal tract adverse reaction [14, 15]. Nevertheless, the powerful cytotoxicity of maytansinoids would make them valuable for anticancer therapies if tissue-specific drug delivery approaches are employed.
To achieve more active targeting, maytansinoids-loaded nanoparticle surface could be immobilized by functional molecules which can recognize and adhere to biomarkers on the surface of target cancer cells. Among targeting agents directed to the membrane-bound and tumor-associated receptors, folate (FA) has been widely utilized for targeted delivery of drug-loaded nanoparticles into FR+ tumor cells as a ligand for a folate receptor (FR) overexpressed in a wide range of tumors including those of the ovary, brain, kidney, breast, and myeloid [16–18]. Recently, it has been reported that FA-mediated delivery of drug-loaded nanoparticles can enable binding, promote uptake, and increase cytotoxicity to cancer cells in vitro/vivo[19–22].
In the present study, DM1-loaded-core PLA-TPGS copolymer nanoparticles (DM1-NPs) immobilized with FA which can enhance tumor cell-targeting ability were constructed. Characterization of the FA-modified DM1-loaded-core PLA-TPGS copolymer nanoparticles (FA-DM1-NPs), including size and zeta potential, was carried out. And drug entrapment efficiency, drug loading efficiency, and release properties in vitro were also tested. The targeting effect of FA-DM1-NPs was investigated in vitro through the uptake of fluorescent nanoparticles by FR+ MCF-7/HER2 cells. The results demonstrated that the FA-DM1-NPs and the stable DM1 methyl thioether derivative (S-DM1) could inhibit cell proliferation, arrest the mitotic process, and induce apoptosis in association with suppression of microtubule dynamic stability.
Human breast adenocarcinoma cell line MCF-7/HER2(ER+, HER2-HIGH) was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). TPGS, 4′-6′-diamino-2-phenylindole (DAPI), and PLA (Mw approximately 25,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA). DM1 and S-DM1 was commercialized by Genentech. FA-PLA-TPGS copolymers (Mw approximately 23,000) were obtained from the Graduate School at Shenzhen, Tsinghua University. Antibodies against caspase-3/-8/-9 were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibodies against Bcl-2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All chromatographic solvents were of high-performance liquid chromatography (HPLC)-grade quality. And all other chemicals used were of the highest grade commercially available.
Fabrication of DM1-loaded nanoparticles
A modified nanoprecipitation method was used to entrap DM1 into the FA-PLA-TPGS NPs [23, 24]. Briefly, a pre-weighed amount of DM1 drug powder and 100 mg of FA-PLA-TPGS copolymer were dissolved in 8 mL of acetone by vortexing and sonication. The resulting nanoparticle suspension was stirred at room temperature overnight to remove acetone completely. The nanoparticle suspension was centrifuged at 25,000 rpm for 15 min, and then washed 2 to 3 times to remove the emulsifier and unloaded drug. This mixture was dropwise added into 100 mL 0.03% TPGS aqueous solution under stirring. In the end, the dispersion was lyophilized 48 h for further use. DM1-loaded PLA-TPGS NPs (DM1-PLA-TPGS-NPs) coumarin 6-loaded star FA-PLA-TPGS-NPs (coumarin 6-NPs), and linear FA-PLA-TPGS nanoparticles used as control were fabricated in a similar manner.
Characterization of DM1-loaded nanoparticles
Size, surface charge, and morphology of the NPs
The nanoparticle size and zeta potential were determined by Malvern Mastersizer 2000 (Zetasizer Nano ZS90, Malvern Instruments Ltd., Malvern, Worcestershire, UK). All measurements were measured at room temperature after equilibration for 10 min. Average size and zeta potential of different NPs were analyzed using a dynamic light-scattering detector (Zetasizer Nano ZS90, Malvern Instruments Ltd., Malvern, Worcestershire, UK). The data were obtained with the average of three measurements.
The surface morphology of nanoparticles was examined by a field emission scanning electron microscopy (FESEM, JEOL JSM-6301 F, JEOL, Tokyo, Japan). To prepare samples for FESEM, the nanoparticles were fixed on the stub by a double-sided sticky tape and then coated with a platinum layer by JFC-1300 automatic fine platinum coater (JEOL, Tokyo, Japan). Morphological examination of FA-PLA-TPGS-NPs was performed using transmission electron microscopy (H600, Hitachi, Tokyo, Japan).
Drug content and entrapment efficiency
Briefly, 10 mg of FA-DM1-NPs were introduced into Eppendorf tubes and dissolved in 1 mL acetonitrile and diluted by 0.1 M citric acid. Meanwhile, the amount of DM1 in the solution was determined by HPLC.
Drug-release assay study
The in vitro release profile of DM1 from FA-DM1-NPs was determined by measuring the residual amount of DM1 presented in the nanoparticles . In brief, 5 mg of accurately weighted lyophilized nanoparticles (FA-DM1-NPs) were put into a centrifuge tube and redispersed in 8 mL phosphate buffer solution (PBS, containing 0.1% w/v Tween 80, pH 7.4). The tube was put into an orbital shaker water bath and vibrated at 130 rpm at 37°C. At certain time intervals, the tube was taken out and centrifuged at 25,000 rpm for 15 min. The supernatant was then transferred into a glass test tube for HPLC analysis. The pellet was resuspended in 8 mL fresh PBS buffer and put back into the shaker bath for subsequent determination. The accumulative release of DM1 from nanoparticles was plotted against time.
Evaluation of the biological function of FA-DM1-NPs
Cellular uptake of FA-coumarin 6-NPs
In this research, coumarin 6 served as a model control molecule, which can be entrapped in star-shaped FA-PLA-TPGS NPs for qualitative and quantitative studying on cellular uptake by MCF-7/HER2 cells. Cells incubated with 250 μg/mL coumarin 6-NPs at 37°C for determined time (12, 24, and 36 h) were rinsed with cold PBS solution three times, and then fixed by methanol for 25 min. Cells were stained with DAPI for 30 min to display the nuclei and rinsed twice with a PBS solution [26, 27]. Tumor cells were observed by using confocal laser scanning microscopy (CLSM; LSM 410, Zeiss, Jena, Germany) with an imaging software.
In vitro cytotoxicity of FA-DM1-NPs
MCF-7/HER2 cells were seeded in 96-well plates at the density of 5 × 103 viable cells per well in 100 μL of culture medium and incubated overnight. Cells were then treated with various suspension concentrations ranging from 0.001 to 10.0 μg/mL of DM1 and FA-DM1-NPs for 48 and 72 h at 37°C in a CO2 incubator. At certain time intervals, the nanoparticles were replaced with DMEM containing MTT (5 mg/mL) and cells were then incubated for an additional 4 h. MTT was aspirated off, and DMSO was added to each well to solubilize the formazan crystals formed in viable cells. The absorbance of each well was recorded at 570 nm using a 96-well microplate reader. Viability of untreated cells was set at 100%, and absorbance of wells with medium and without cells was set as zero. All of the results were from at least triplicate experiments. The inhibitory concentration IC50, the drug concentration at which cell growth was inhibited by 50% relative to untreated control cells, was calculated by curve fitting of the cell viability vs. drug concentration data [28, 29].
In vivo assay of drug sensitivity
The Administrative Committee on Animal Research in the Anhui University of Science and Technology approved all the protocols for the proposed human breast cancer cell lines and animal experiments. Female BALB/c nude mice of 15 to 20 g and 4 to 5 weeks old were purchased from the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science. MCF-7/HER2 cells in the medium were inoculated subcutaneously to mice in the amount of 2 × 106 cells per mouse at the right axilla, and the subcutaneous tumor growth in each mouse was monitored. The length and width of tumors were determined by a vernier caliper, and the tumor volume (V) was calculated as V = d2 × D/2, where d and D are the shortest and the longest diameter of the tumor in mm, respectively . When the tumor volume reached approximately 50 mm3 (set as the 0 day), treatments were performed. The mice were randomly divided into three groups (each group has 10 mice, n =10). The two formulations of DM1, i.e., the drug FA-DM1-NPs and Kadcyla®, were injected via intra-tumoral at a single dose of 10 mg DM1/kg in PBS on days 10, 13, and 16. PBS served as the control. Mice were sacrificed by decapitation 30 days after treatment. The terminal tumor weight (mg) was determined and applied to evaluate the antitumor effects.
Xenograft tumor tissues were fixed in phosphate-buffered formalin, embed in paraffin, and cut in 4 μm thickness. Sections were deparaffinized and stained with hematoxylin-eosin (H&E). For immunohistochemistry (IHC), tissue sections were covered with 10 mM sodium citrate buffer, pH 6.0, and heated in a convection steamer for 1 h. After being blocked in 5% normal goat blocking serum for 30 min, it was incubated with primary antibody for 1 h, and next as IHC operation.
Fluorescence in situ hybridization (FISH)
Her2 gene copy numbers were determined by using the dual-color fluorescence in situ hybridization (FISH). After trypsinization and washing with PBS, the cells were fixed with methanol-acetic acid (3:1) and air-dried on slides. A bacterial artificial chromosome (BAC) clone specific to Her2 DNA was labeled with dUTP-FITC (Fermentas, Burlington, Canada) and the chromosome 17 centromere probe (p17H8) was labeled with chromatide Alexa Fluor 594-5-dUTP (Invitrogen, Carlsbad, CA, USA) using nick translation, and FISH was performed as described previously .
The expression levels of procaspase-3/-8/-9 and Bcl-2 in the breast cancer cells treated with S-DM1 or FA-DM1-NPs were analyzed by Western blot. Protein was extracted and separated by SDS-PAGE and transferred to nitrocellulose membranes. After being blocked in 5% bovine serum albumin (w/v) at room temperature for 1 h, the membranes were rinsed and incubated at 4°C overnight with primary anti-total and procaspase-3/-8/-9, β-actin antibody (1:1,000). The membranes were then washed and incubated with secondary antibody (1:2,000 ~ 3,000) at room temperature for 1 h, developed with chemiluminescence ECL reagent (LumiGold, SignaGen, Gaithersburg, MD, USA), and exposed to Hyperfilm MP (GE Healthcare, Piscataway, NJ, USA). Tumor samples were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, supplemented with complete Mini protease inhibitors) and equal amounts of protein were subjected to Western blotting analysis. The protein levels were normalized to β-actin.
All experiments were performed at least three times unless otherwise mentioned. Student’s t test statistical analysis was carried out with SPSS 13.0 software, with p <0.05 considered to indicate a significant difference.
Size, surface morphology, zeta potential, and entrapment efficiency
Characterization of DM1-loaded nanoparticles
Particle size (nm)
123.7 ± 3.9
-19.5 ± 2.6
126.6 ± 3.5
-12.0 ± 2.1
In vitro release profiles
Cellular uptake of fluorescent FA-PLA-TPGS nanoparticles
In vitro MCF-7/HER2 cells viability and sensitivity
Effect of drug on the expression levels of apoptosis-related proteins
Effect of DM1 NPs on xenografts
Synergistic antitumor activities could be obtained by the use of combinations of S-DM1 and star FA-PLA-TPGS-NPs. As shown in Figure 8, residual tumor cells were found at the inoculation in two of ten samples (2/10) in the FA-DM1-NP treatment group. Tumor cell nuclear structure showed that cell division phase decreased significantly compared to pre- FA-DM1-NP treatment. The fraction of proliferating cells (confirmed by Ki-67 immunohistochemical staining) among tumor cells was small compared to pre-treatment (Figure 8). Confirmed by FISH, oncogene Her2 was amplified in MCF-7/HER2 cells of the pre- and postdrug treatment. But the Her2 level at pre-treatment was much higher than that at post-treatment (Figure 8). Tumor cell division phase index Ki-67 (IHC) positive ratio and the expression level of HER2 (IHC) in MCF-7/HER2 cells of the FA-DM1-NP post-treatment were lower compared with those of pre-treatment. HER2 is an excellent target for an antibody-drug conjugate as it is highly overexpressed on HER2-positive cancer cells. After binding to HER2, DM1 is internalized by endocytosis and degraded in lysosomes, causing the release of the active metabolite DM1 which inhibits Her2- and HER2-positive cancer cell division and induces cell death by blocking the spindle apparatus. So, after FA-DM1-NP pre-treatment, tumor cell division phase index-, Her2 oncogene-, and HER2-positive cancer cells significantly reduced compared with FA-DM1-NP post-treatment. In conclusion, the FA-DM1-NPs offered considerable potential as an ideal candidate for in vivo drug delivery.
There is no doubt that DM1 has provided significant clinical benefit in patients with breast cancer [36, 37]. Nevertheless, primary (de novo) and secondary (acquired) resistance and side effects represent real clinical challenges [25, 40]. FA-DM1-NPs showed high stability and desired surface properties in favor of cellular uptake. Meanwhile, FA-DM1-NPs can be targeted to FR+ cancer cells and improve DM1 concentration in the target tissues, reduce nonspecific distribution and side effects of DM1, inhibit tumor cell proliferation, and promote apoptosis of tumor cells in the effects of biological synergy, which has a potential to establish new treatment paradigms.
The authors are grateful for the Open Research Fund Program of the State Key Laboratory of Virology of China (no. 2014KF004), the National High Technology Research and Development Program (863 Program) (no. 2011AA02A111), and the 2011 Infectious Disease Prevention and Control Technology major project (no. 2012ZX10004903).
- Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X: Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 2014, 35(23):6118–6129. 10.1016/j.biomaterials.2014.04.034View ArticleGoogle Scholar
- Wang M, Zhang Y, Sun B, Sun Y, Gong X, Wu Y, Zhang X, Kong W, Chen Y: Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine. Biol Pharm Bull 2014, 37(5):740–747. 10.1248/bpb.b13-00591View ArticleGoogle Scholar
- Maeda H, Sawa T, Konno T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001, 74(1–3):47–61.View ArticleGoogle Scholar
- Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC: Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73(8):2412–2417. 10.1158/0008-5472.CAN-12-4561View ArticleGoogle Scholar
- Tan GR, Feng SS, Leong DT: The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. Biomaterials 2014, 35(9):3044–3051. 10.1016/j.biomaterials.2013.12.033View ArticleGoogle Scholar
- Zhao J, Feng SS: Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs. Biomaterials 2014, 35(10):3340–3347. 10.1016/j.biomaterials.2014.01.003View ArticleGoogle Scholar
- Sendur MA, Aksoy S, Ozdemir Y, Zengin N, Altundag K: Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? J BUON 2013, 18(3):801.Google Scholar
- Bighin C, Pronzato P, Del Mastro L: Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Future Oncol 2013, 9(7):955–957. 10.2217/fon.13.74View ArticleGoogle Scholar
- Gradishar WJ: Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol 2013, 24(10):2492–2500. 10.1093/annonc/mdt217View ArticleGoogle Scholar
- Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, Yi JH, Girish S, Dybdal N, Reynolds T: Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 2013, 273(2):298–313. 10.1016/j.taap.2013.09.003View ArticleGoogle Scholar
- Kümler I, Tuxen MK, Nielsen DL: A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014, 40(2):259–270. 10.1016/j.ctrv.2013.09.002View ArticleGoogle Scholar
- Venghateri JB, Gupta TK, Verma PJ, Kunwar A, Panda D: Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. PLoS One 2013, 8(10):e75182. 10.1371/journal.pone.0075182View ArticleGoogle Scholar
- Lopus M, Yenjerla M, Wilson L: Microtubule dynamics. In Encyclopedia of Chemical Biology. 3. Edited by: Begley TP. New Jersey: John Wiley & Sons; 2009:153–160.Google Scholar
- Haddley K: Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. Drugs Today (Barc) 2013, 49(11):701–715. 10.1358/dot.2013.49.11.2020937View ArticleGoogle Scholar
- Thery JC, Spano JP, Azria D, Raymond E, Penault LF: Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 2014, 50(5):892–901. 10.1016/j.ejca.2014.01.003View ArticleGoogle Scholar
- Ye P, Zhang W, Yang T, Lu Y, Lu M, Gai Y, Ma X, Xiang G: Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int J Nanomedicine 2014, 9: 2167–2178.View ArticleGoogle Scholar
- Hu Y, Ma B, Zhang Y, Wang M: Small molecule-folic acid modification on nanopatterned PDMS and investigation on its surface property. Biomed Microdevices 2014, 16(3):487–497. 10.1007/s10544-014-9851-7View ArticleGoogle Scholar
- Leamon CP, Vlahov IR, Reddy JA, Vetzel M, Santhapuram HK, You F, Bloomfield A, Dorton R, Nelson M, Kleindl P, Vaughn JF, Westrick E: Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship. Bioconjug Chem 2014, 25(3):560–568. 10.1021/bc400441sView ArticleGoogle Scholar
- Shi J, Wang L, Gao J, Liu Y, Zhang J, Ma R, Liu R, Zhang Z: A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials 2014, 35(22):5771–5784. 10.1016/j.biomaterials.2014.03.071View ArticleGoogle Scholar
- Zheng M, Zhao P, Luo Z, Gong P, Zheng C, Zhang P, Yue C, Gao D, Ma Y, Cai L: Robust ICG theranostic nanoparticles for folate targeted cancer imaging and highly effective photothermal therapy. ACS Appl Mater Interfaces 2014, 6(9):6709–6716. 10.1021/am5004393View ArticleGoogle Scholar
- Torchilin V: Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131–135. 10.1016/j.addr.2010.03.011View ArticleGoogle Scholar
- Maeda H: Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010, 21(5):797–802. 10.1021/bc100070gView ArticleGoogle Scholar
- Zhu Q, Feng C, Liao W, Zhang Y, Tang S: Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell Int 2013, 13(1):65. 10.1186/1475-2867-13-65View ArticleGoogle Scholar
- Wang R, Hu X, Wu S, Xiao H, Cai H, Xie Z, Huang Y, Jing X: Biological characterization of folate-decorated biodegradable polymer-platinum(II) complex micelles. Mol Pharm 2012, 9(11):3200–3208. 10.1021/mp3002914View ArticleGoogle Scholar
- Bartsch R, Berghoff AS, Preusser M: Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 2014, 116(1):205–206. 10.1007/s11060-013-1257-5View ArticleGoogle Scholar
- Park JH, Lee JY, Termsarasab U, Yoon IS, Ko SH, Shim JS, Cho HJ, Kim DD: Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery. Int J Pharm 2014, 473(1–2):426–433.View ArticleGoogle Scholar
- Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS: Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials 2013, 34(25):6058–6067. 10.1016/j.biomaterials.2013.04.052View ArticleGoogle Scholar
- Zhang Y, Yang H, Barnie PA, Yang P, Su Z, Chen J, Jiao Z, Lu L, Wang S, Xu H: The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci 2014, 11(6):608–613. 10.7150/ijms.8428View ArticleGoogle Scholar
- Niu G, Carter WB: Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007, 67(4):1487–1493. 10.1158/0008-5472.CAN-06-3155View ArticleGoogle Scholar
- Tang X, Cai S, Zhang R, Liu P, Chen H, Zheng Y, Sun L: Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment. Nanoscale Res Lett 2013, 8(1):420. 10.1186/1556-276X-8-420View ArticleGoogle Scholar
- Abdelmontalab FY, Fadl EI, Abushama H, Kreskowski K, Liehr T: Molecular cytogenetic study of the NF2 gene deletion in meningioma in Sudanese patients. Balkan J Med Genet 2013, 16(2):29–32.Google Scholar
- Merkhofer EC, Cogswell P, Baldwin AS: Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 2010, 29(8):1238–1248. 10.1038/onc.2009.410View ArticleGoogle Scholar
- YSlamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783–792. 10.1056/NEJM200103153441101View ArticleGoogle Scholar
- Khoshgard K, Hashemi B, Arbabi A, Rasaee MJ, Soleimani M: Radiosensitization effect of folate-conjugated gold nanoparticles on HeLa cancer cells under orthovoltage superficial radiotherapy techniques. Phys Med Biol 2014, 59(9):2249–2263. 10.1088/0031-9155/59/9/2249View ArticleGoogle Scholar
- Li L, Yang Q, Zhou Z, Zhong J, Huang Y: Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting. Biomaterials 2014, 35(19):5171–5187. 10.1016/j.biomaterials.2014.03.027View ArticleGoogle Scholar
- Tavassolian F, Kamalinia G, Rouhani H, Amini M, Ostad SN, Khoshayand MR, Atyabi F, Tehrani MR, Dinarvand R: Targeted poly (l-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells. Int J Pharm 2014, 467(1–2):123–138.View ArticleGoogle Scholar
- Vijayakumar MR, Muthu MS, Singh S: Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy. Expert Opin Drug Deliv 2013, 10(4):529–543. 10.1517/17425247.2013.758632View ArticleGoogle Scholar
- Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, Teng CH, Lin CH, Johnson MD, Lin CY, Lee MS: Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol 2010, 177(6):3145–3158. 10.2353/ajpath.2010.100228View ArticleGoogle Scholar
- Zheng J, Wang H, Yao J, Zou X: More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro. Pharmazie 2014, 69(1):38–42.Google Scholar
- Barok M, Tanner M, Köninki K, Isola J: Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011, 13(2):R46. 10.1186/bcr2868View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.